Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

(2018) Johanna C. Bendell et al.   CLINICAL CANCER RESEARCH

Recent advances in molecular-targeted therapy for oral cancer

(2017) M. Kioi   INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Dynamics of regulatory T cells (Tregs ) in patients with oral squamous cell carcinoma

(2017) Sadhna Aggarwal et al.   JOURNAL OF SURGICAL ONCOLOGY

Concurrent PI3K and NF-κB activation drives B-cell lymphomagenesis

(2016) H Y Jin et al.   LEUKEMIA

Autophagy mediates pharmacological lifespan extension by spermidineand resveratrol

(2016) Eugenia Morselli et al.   Aging-US

Galectin-1 and galectin-3: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population

(2015) Sadhna Aggarwal et al.   CLINICA CHIMICA ACTA

Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer

(2015) Sadhna Aggarwal et al.   TUMOR BIOLOGY

Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance

(2014) Sadhna Aggarwal et al.   CLINICA CHIMICA ACTA

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

(2014) L Chang et al.   Cell Death & Disease

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma

(2012) Richa Garg et al.   CLINICA CHIMICA ACTA

Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis

(2012) Azhar R. Hussain et al.   PLoS One

Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches

(2012) Sabrina Daniela da Silva et al.   Frontiers in Pharmacology

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

(2011) Sandrine Guillard et al.   CELL CYCLE

Advances in the systemic treatment of head and neck cancers

(2010) Pol Specenier et al.   CURRENT OPINION IN ONCOLOGY

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma

(2010) Ho-Shin Gwak et al.   INTERNATIONAL JOURNAL OF CANCER

Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent

(2010) Vaishali Kapoor et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

(2010) D. Koul et al.   NEURO-ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma

(2008) J. S. Chen et al.   MOLECULAR CANCER THERAPEUTICS